- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03058601
Outcomes in UK ACS Patients Prescribed Ticagrelor
Health Outcomes of Patients With Acute Coronary Syndromes Prescribed Ticagrelor in UK Primary Care: a Retrospective Cohort Study
Cohort study using data from Clinical Practice Research Datalink (CPRD). The study cohort includes all patients who received at least one prescription for ticagrelor for the first time between December 2010 and March 2015, following ACS. Patient baseline characteristics will be described: (Age, Gender, Body Mass Index, Smoking status, Sociodemographic status), type of ACS and interventions, CV history and comorbidities, bleeding and respiratory history.
The following outcomes will be examined: Incidence of vascular events (composite MI, Stroke, vascular death, specific vascular event and all cause death), incidence of bleeding and incidence of dysponea. Time to event for vascular events, bleeding and dyspnoea.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Luton, Storbritannien
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- First prescription (index date) for ticagrelor between Dec 2010 and Mar 2015
- At least 12 months history in database prior to first ticagrelor prescription
- Linkage to Hospital Episode Statistics (HES)
- Acute Coronary Syndrome (ACS) event in the three months prior to and including the index date
Exclusion Criteria:
Primary care prescription for clopidogrel or prasugrel between the ACS date and the index date
Studieplan
Hur är studien utformad?
Designdetaljer
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Incidence of composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Incidence of myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Incidence of all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Incidence of stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Incidence of vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for composite outcome of myocardial infarction (MI), Stroke or death from vascular causes in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for myocardial infarction (MI) in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for all cause death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for stroke in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for vascular death in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Incidence of bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Incidence of dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for bleeding in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Time to event for dyspnoea in patients treated with ticagrelor in primary care following Acute Coronary Syndrome (ACS)
Tidsram: From index date up to 12 months
|
From index date up to 12 months
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- D5130R00027
- EUPAS17107 (Registeridentifierare: ENCePP)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Akut koronarsyndrom
-
IRCCS Policlinico S. DonatoRekryteringAnomalous aortic origin of the coronary artery (AAOCA)Italien
-
Biotronik AGAvslutadde Novo Lesions in Native coronary arteriesNederländerna, Schweiz, Tyskland, Belgien
-
Osaka General Medical CenterAvslutadEmergent coronary procedurJapan
-
Claudia SpiesAvslutadOmskärelse, Meatotomy eller Distal Coronary Correction of HypospadiaTyskland
-
Tel-Aviv Sourasky Medical CenterAvslutadKonsekutiva ämnen som är lämpliga för en kranskärlssjukdom | Angioplastik av de Novo lesion(er) i Native Coronary | Artärer bör undersökas för behörighet. | Totalt antal 200 patienter som uppfyller urvalet | Kriterier och villig att underteckna det informerade samtycket | vara inskriven i provet.Israel
-
RenJi HospitalAvslutadST Segment Elevation Myokardinfarkt | Coronary Slow Flow FenomenKina
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.AvslutadTidigare behandlat myelodysplastiskt syndrom | Myelodysplastiskt syndrom | Terapierelaterat myelodysplastiskt syndrom | Sekundärt myelodysplastiskt syndrom | Refraktärt högrisk myelodysplastiskt syndromFörenta staterna
-
National Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)AvslutadTidigare behandlade myelodysplastiska syndrom | Sekundära myelodysplastiska syndrom | de Novo myelodysplastiska syndromFörenta staterna
-
Institut de Recherches Internationales ServierServier Bio-Innovation LLCHar inte rekryterat ännuMyelodysplastiska syndrom (MDS) | Hypometylerande medel (HMA) Naiva myelodysplastiska syndrom (MDS)